| Jeffrey P Karls, DO | |
|
30 Pinnacle Dr Ste 101a, Clarion, PA 16214-3882 | |
| (814) 297-7070 | |
| (814) 297-7072 |
| Full Name | Jeffrey P Karls |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 30 Pinnacle Dr Ste 101a, Clarion, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194791673 | NPI | - | NPPES |
| P001985 | Other | PA | GATEWAY |
| P00716884 | Other | MO | RAILROAD MEDICARE |
| 0012805170009 | Medicaid | PA |
| Entity Name | Primary Health Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417932609 PECOS PAC ID: 9234046228 Enrollment ID: O20031124000553 |
News Archive
It is Australia's turn to get a new National Health Performance Authority after the Victorian Government abandoned its opposition to the creation of the body. According to sources in a meeting of federal, state and territory health ministers in Melbourne this week all groups have agreed in principle to the establishment of the authority which will monitor and report on the performance of hospitals and health services.
EKF Molecular Diagnostics has agreed a collaboration with specialist medtech company ANGLE plc, to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF Molecular's PointMan™ DNA enrichment technology as a liquid biopsy. If successful, the resulting simple blood test could enable the investigation of unexpected ultra-low level mutations in a patient's cancer for personalised cancer care.
A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes). The study was published online today in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. The paper will appear in the July 28 print issue of JAMA.
The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey P Karls, DO 100 Shenango Ave, Sharon, PA 16146-1503 Ph: (814) 297-7070 | Jeffrey P Karls, DO 30 Pinnacle Dr Ste 101a, Clarion, PA 16214-3882 Ph: (814) 297-7070 |
News Archive
It is Australia's turn to get a new National Health Performance Authority after the Victorian Government abandoned its opposition to the creation of the body. According to sources in a meeting of federal, state and territory health ministers in Melbourne this week all groups have agreed in principle to the establishment of the authority which will monitor and report on the performance of hospitals and health services.
EKF Molecular Diagnostics has agreed a collaboration with specialist medtech company ANGLE plc, to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF Molecular's PointMan™ DNA enrichment technology as a liquid biopsy. If successful, the resulting simple blood test could enable the investigation of unexpected ultra-low level mutations in a patient's cancer for personalised cancer care.
A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes). The study was published online today in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. The paper will appear in the July 28 print issue of JAMA.
The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.
› Verified 6 days ago
Mahreen Nizarali Gilani, Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Clarion, PA 16214 Phone: 814-226-9500 | |
Dr. Erin Minich Bowser, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 18 Sportsman Dr, Clarion, PA 16214 Phone: 814-226-6062 | |
Saad Shaukat, Family Medicine Medicare: Medicare Enrolled Practice Location: 24 Doctors Ln Ste 202, Clarion, PA 16214 Phone: 814-226-2500 Fax: 814-226-2501 | |
Omais Ahmed, Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Clarion, PA 16214 Phone: 814-226-9500 | |
Panayiota Voutsinas, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 24 Doctors Ln, Suite 202, Clarion, PA 16214 Phone: 814-226-2500 | |
Daniel B Bolton, Family Medicine Medicare: Medicare Enrolled Practice Location: 24 Doctors Ln Ste 202, Clarion, PA 16214 Phone: 814-226-2500 Fax: 814-226-2501 |